首頁 > 市場調查報告書 > 製藥

癌症呼吸器

市場調查報告書

商品編碼

1812434

肺癌市場按類型、藥物類別、分子類型、給藥途徑、疾病分期、年齡層、性別、分銷管道、最終用戶和地區分類

Lung Cancer Market, By Type, By Drug Class, By Molecule Type, By Route of Administration, By Stage of Disease, By Age Group, By Gender, By Distribution Channel, By End User, By Geography

出版日期: 2025年08月26日 | 出版商:

Coherent Market Insights | 英文 130 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計 2025 年肺癌市場價值將達到 281.2 億美元，到 2032 年預計將達到 645.3 億美元，2025 年至 2032 年的年複合成長率（CAGR）為 12.6%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	281.2億美元
效能數據	從2020年到2024年	預測期	2020年至2024年
預測期：2025-2032年複合年成長率：	12.60%	2032年的價值預測	645.3億美元

全球肺癌市場是癌症治療領域最重要的細分市場之一，其驅動力來自肺癌這一持續存在的全球性挑戰，而肺癌是癌症相關死亡的主要原因。這種惡性腫瘤每年影響數百萬患者，其中非小細胞肺癌 (NSCLC) 約佔所有病例的 85%，小細胞肺癌 (SCLC) 佔其餘 15%。該市場治療性介入，包括化療、標靶治療、免疫治療、放射線治療和手術，以及診斷工具和支持性治療。

吸菸習慣、環境污染物、職業危害和遺傳易感性導致的癌症盛行率不斷上升，持續刺激全球癌症需求。精準醫療方法的引入，例如生物標記主導療法、免疫查核點抑制劑和蛋白酪氨酸激酶抑制劑，見證了癌症治療領域的突破，並顯著改善了患者的預後。醫療基礎設施的改善、人們對早期檢測項目的認知不斷提高，以及製藥公司對研發活動的大力投入，共同塑造市場的發展軌跡。

市場動態

全球肺癌市場受到多種促進因素的推動，這些因素共同促成了其強勁的成長軌跡，但同時，它也面臨著某些阻礙因素，這些因素在減緩擴張速度的同時，也為未來的市場發展提供了重大機會。關鍵的市場促進因素包括由於菸草消費量增加、空氣污染、職業性致癌物質暴露和遺傳易感性導致的全球肺癌發病率上升，這些因素共同擴大了需要治療性介入的患者群體。

免疫療法的突破性進展，尤其是PD-1/PD-L1抑制劑等免疫查核點抑制劑，改變了治療模式，並創造了巨大的市場機會。同時，針對EGFR、ALK和ROS1等特定基因突變的標靶治療的開發，使得個體化治療方案得以實現，並獲得了卓越的療效。新興國家醫療基礎設施的改善、醫療支出的增加以及透過篩檢計畫提高早期診斷意識，進一步推動了市場的成長。

然而，市場擴張面臨著巨大的限制因素，包括創新癌症治療的成本非常高，限制了藥物的獲取，尤其是在新興市場；嚴格的法律規範延長了藥物核准時間；以及藥物開發過程的複雜性，需要大量投資但結果不確定。

專利到期將導致現有藥物面臨定價壓力並損失市場佔有率。然而，透過開發聯合治療來提高療效、拓展尚未開發的地理市場、推動伴隨診斷技術進步以實現個人化醫療，以及整合人工智慧和機器學習技術以改善診斷和治療方案，這些都蘊藏著巨大的商機。對早期癌症治療的日益關注、新型藥物輸送系統的開發以及製藥公司與研究機構之間合作的加強，都為市場擴張和技術創新開闢了新的途徑。

本次調查的主要特點

本報告對全球肺癌市場進行了詳細分析，提供了預測期（2025-2032 年）的市場規模（十億美元）和年複合成長率（CAGR%），以 2024 年為基準年。
它還強調了各個領域的潛在商機，並說明了該市場有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
它根據公司亮點、產品系列、關鍵亮點、財務業績和策略等參數概述了全球肺癌市場的主要企業。
本報告的見解將使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
全球肺癌市場報告涉及該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
透過用於分析全球肺癌市場的各種策略矩陣，相關人員將更容易做出決策。

Hoffmann-La Roche Ltd.
Novartis AG
AstraZeneca plc
Bristol Myers Squibb Company
Merck and Co., Inc.（MSD）
Pfizer Inc.
Eli Lilly and Company
Johnson and Johnson（Janssen Biotech, Inc.）
Amgen Inc.
AbbVie Inc.
Sanofi SA
Takeda Pharmaceutical Company Limited
Daiichi Sankyo Company, Limited
Astellas Pharma Inc.
Regeneron Pharmaceuticals, Inc.

第 15 章分析師建議

機會
分析師觀點
Coherent Opportunity Map

第16章參考文獻與調查方法

參考
調查方法
關於出版商

簡介目錄

Product Code: CMI8494

Lung Cancer Market is estimated to be valued at USD 28.12 Bn in 2025 and is expected to reach USD 64.53 Bn by 2032, growing at a compound annual growth rate (CAGR) of 12.6% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 28.12 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	12.60%	2032 Value Projection:	USD 64.53 Bn

The global lung cancer market represents one of the most critical segments within the oncology therapeutics landscape, driven by the persistent challenge of lung cancer as the leading cause of cancer-related mortality worldwide. This malignancy affects millions of patients annually, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all cases, while small cell lung cancer (SCLC) comprises the remaining 15%. The market encompasses a comprehensive spectrum of therapeutic interventions including chemotherapy, targeted therapy, immunotherapy, radiation therapy, and surgical procedures, alongside diagnostic tools and supportive care solutions.

Rising prevalence rates attributed to smoking habits, environmental pollutants, occupational hazards, and genetic predispositions continue to fuel demand globally. The therapeutic landscape has witnessed revolutionary advancements through the introduction of precision medicine approaches, including biomarker-driven treatments, immune checkpoint inhibitors, and tyrosine kinase inhibitors that have significantly improved patient outcomes. Healthcare infrastructure development, increasing awareness about early detection programs, and substantial investments in research and development activities by pharmaceutical companies are collectively shaping the market trajectory.

Market Dynamics

The global lung cancer market is propelled by multiple driving factors that collectively contribute to its robust growth trajectory, while simultaneously facing certain constraints that moderate expansion rates, yet presenting significant opportunities for future development. Primary market drivers include the escalating global incidence of lung cancer due to increasing tobacco consumption, air pollution, occupational exposure to carcinogens, and genetic susceptibilities, which collectively expand the patient population requiring therapeutic interventions.

The revolutionary advancement in immunotherapy treatments, particularly immune checkpoint inhibitors such as PD-1/PD-L1 inhibitors, has transformed treatment paradigms and created substantial market opportunities, while targeted therapy developments focusing on specific genetic mutations like EGFR, ALK, and ROS1 have enabled personalized treatment approaches that demonstrate superior efficacy rates. Healthcare infrastructure improvements in emerging economies, coupled with increasing healthcare expenditure and growing awareness about early diagnosis through screening programs, further accelerate the market growth.

However, market expansion faces significant restraints including the extremely high costs associated with innovative cancer treatments, which limit accessibility particularly in developing regions, stringent regulatory frameworks that prolong drug approval timelines, and the complex nature of drug development processes that require substantial investments with uncertain outcomes.

Patent expiration of blockbuster drugs creates pricing pressures and market share erosion for established players. Nevertheless, substantial opportunities exist through the development of combination therapies that enhance treatment efficacy, expansion into untapped geographical markets, advancement in companion diagnostics for personalized medicine, and the integration of artificial intelligence and machine learning technologies for improved diagnosis and treatment selection. The growing focus on early-stage cancer treatment, development of novel drug delivery systems, and increasing collaborations between pharmaceutical companies and research institutions present additional avenues for market expansion and innovation.

Key Features of the Study

This report provides in-depth analysis of the global lung cancer market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global lung cancer market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include F. Hoffmann-La Roche Ltd, Novartis AG, AstraZeneca plc, Bristol Myers Squibb Company, Merck and Co., Inc. (MSD), Pfizer Inc., Eli Lilly and Company, Johnson and Johnson (Janssen Biotech, Inc.), Amgen Inc., AbbVie Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company, Limited, Astellas Pharma Inc., and Regeneron Pharmaceuticals, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global lung cancer market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global lung cancer market.

Market Segmentation

Type Insights (Revenue, USD Bn, 2020 - 2032)
- Non-Small Cell Lung Cancer (NSCLC)
- Adenocarcinoma
- Squamous Cell Carcinoma
- Large Cell Carcinoma
- Small Cell Lung Cancer (SCLC)
- Lung Carcinoid Tumor
Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
- Cytotoxic Chemotherapy
- Alkylating agents (cisplatin, carboplatin, etc.)
- Antimetabolites (pemetrexed, gemcitabine)
- Mitotic inhibitors (taxanes: paclitaxel, docetaxel)
- Topoisomerase inhibitors (etoposide, irinotecan)
- Others
- Targeted Therapy
- EGFR Inhibitors (Erlotinib, etc.)
- ALK Inhibitors (Crizotinib, etc.)
- ROS1 Inhibitors (Entrectinib, etc.)
- BRAF/MEK Inhibitors (Dabrafenib, etc.)
- MET Inhibitors (Capmatinib, etc.)
- RET Inhibitors (Selpercatinib, etc.)
- HER2 Inhibitors (Trastuzumab, etc.)
- Immunotherapy
- PD-1 Inhibitors (Nivolumab, etc.)
- PD-L1 Inhibitors (Atezolizumab, etc.)
- CTLA-4 Inhibitors (Ipilimumab, etc.)
- Other Combination Therapeutics
Molecule Type Insights (Revenue, USD Bn, 2020 - 2032)
- Small Molecules
- Biologics
Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Parenteral
- Oral
Stage of Disease Insights (Revenue, USD Bn, 2020 - 2032)
- Early-stage (Stage I-II)
- Locally Advanced (Stage III)
- Metastatic/Advanced (Stage IV)
Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Adult
- Pediatric
- Geriatric
Gender Insights (Revenue, USD Bn, 2020 - 2032)
- Male
- Female
Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals
- Diagnostic Laboratories
- Specialty Cancer Clinics
- Homecare Settings
- Others (Research and Academic Institutes, etc.)
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Hoffmann-La Roche Ltd.
- Novartis AG
- AstraZeneca plc
- Bristol Myers Squibb Company
- Merck and Co., Inc. (MSD)
- Pfizer Inc.
- Eli Lilly and Company
- Johnson and Johnson (Janssen Biotech, Inc.)
- Amgen Inc.
- AbbVie Inc.
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited
- Daiichi Sankyo Company, Limited
- Astellas Pharma Inc.
- Regeneron Pharmaceuticals, Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Lung Cancer Market, By Type
- Global Lung Cancer Market, By Drug Class
- Global Lung Cancer Market, By Molecule Type
- Global Lung Cancer Market, By Route of Administration
- Global Lung Cancer Market, By Stage of Disease
- Global Lung Cancer Market, By Age Group
- Global Lung Cancer Market, By Gender
- Global Lung Cancer Market, By Distribution Channel
- Global Lung Cancer Market, By End User
- Global Lung Cancer Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Driver
- Restraint
- Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Lung Cancer Market, By Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Non-Small Cell Lung Cancer (NSCLC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Adenocarcinoma
  - Squamous Cell Carcinoma
  - Large Cell Carcinoma
Small Cell Lung Cancer (SCLC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Lung Carcinoid Tumor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Lung Cancer Market, By Drug Class, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Cytotoxic Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - Alkylating agents (cisplatin, carboplatin, etc.)
  - Antimetabolites (pemetrexed, gemcitabine)
  - Mitotic inhibitors (taxanes: paclitaxel, docetaxel)
  - Topoisomerase inhibitors (etoposide, irinotecan)
  - Others
Targeted Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - EGFR Inhibitors (Erlotinib, etc.)
  - ALK Inhibitors (Crizotinib, etc.)
  - ROS1 Inhibitors (Entrectinib, etc.)
  - BRAF/MEK Inhibitors (Dabrafenib, etc.)
  - MET Inhibitors (Capmatinib, etc.)
  - RET Inhibitors (Selpercatinib, etc.)
  - HER2 Inhibitors (Trastuzumab, etc.)
Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  - PD-1 Inhibitors (Nivolumab, etc.)
  - PD-L1 Inhibitors (Atezolizumab, etc.)
  - CTLA-4 Inhibitors (Ipilimumab, etc.)
Other Combination Therapeutics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Lung Cancer Market, By Molecule Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Small Molecules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Biologics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Lung Cancer Market, By Route of Administration, 2025-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Lung Cancer Market, By Stage of Disease, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Early-stage (Stage I-II)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Locally Advanced (Stage III)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Metastatic/Advanced (Stage IV)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Lung Cancer Market, By Age Group, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Global Lung Cancer Market, By Gender, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

11. Global Lung Cancer Market, By Distribution Channel, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

12. Global Lung Cancer Market, By End User, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Specialty Cancer Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others (Research and Academic Institutes, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

13. Global Lung Cancer Market, By Region, 2020 - 2032, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Stage of Disease, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Stage of Disease, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Stage of Disease, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Stage of Disease, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Stage of Disease, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Stage of Disease, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

14. Competitive Landscape

Hoffmann-La Roche Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck and Co., Inc. (MSD)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Johnson and Johnson (Janssen Biotech, Inc.)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Daiichi Sankyo Company, Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Regeneron Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies